Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

Objective: Domestic PD-1inhibitor tislelizumab has emerged as a promising treatment for Chinese patients with driver-negative advanced or metastatic non-small cell lung cancer (NSCLC). The purpose of our study to evaluate whether tislelizumab is cost-effective as a second- or third-line treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Dongchu, Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Wan, Xiaomin, Tan, Chongqing, Liu, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453816/
https://www.ncbi.nlm.nih.gov/pubmed/36091746
http://dx.doi.org/10.3389/fphar.2022.880280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453816/
https://www.ncbi.nlm.nih.gov/pubmed/36091746
http://dx.doi.org/10.3389/fphar.2022.880280

Ejemplares similares